

08/192,861

ABSTRACT OF THE DISCLOSURE

Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which 5 compounds are specific for tumor necrosis factor- $\alpha$  (TNF $\alpha$ ) or tumor necrosis factor- $\beta$  (TNF $\beta$ ) and which are useful for *in vivo* therapy or diagnosis of TNF $\alpha$ -mediated pathologies and conditions, wherein the anti-TNF compound is selected from the group consisting of at least one of an immunoglobulin 10 variable region, a fragment of a TNF receptor and an anti-TNF peptide, such as a structural analog of a anti-TNF antibody fragment or a TNF receptor fragment.